查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867590

肝细胞生长因子：全球市占率及排名、总收入及需求预测（2025-2031年）

Hepatocyte Growth Factor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 105 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球肝细胞生长因子 (HGF) 市场规模估计为 7,580 万美元，预计到 2031 年将达到 4.26 亿美元，在 2025 年至 2031 年的预测期内，复合年增长率将达到 28.0%。

本报告对近期关税调整和国际战略反制措施对肝细胞生长因子 (HGF) 的跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组进行了全面评估。

肝细胞生长因子（HGF）（或称散播因子（SF））是一种旁分泌细胞生长、运动和形态发生因子。它由间质细胞分泌，主要针对上皮细胞和内皮细胞，但也作用于造血前驱细胞和T细胞。研究表明，它在胚胎器官发育（尤其是肌肉生成）、成体器官再生和创伤治疗中发挥重要作用。

目前，针对HGF通路药物的研发主要分为神经再生和肿瘤两大领域。临床研发管线主要集中在糖尿病神经病变病变、肌萎缩侧索硬化症（ALS）、脊髓损伤、中风以及包括非小细胞肺癌（NSCLC）和胃癌在内的多种固体癌等适应症。在全球范围内，Helixmith、Anges MG和Kringle Pharma等公司正在开发用于治疗神经系统疾病的基因疗法和重组蛋白。 Atira Pharma和AVEO正在开发针对HGF/c-Met轴的小分子和抗体药物，而Exelixis和Molecular Partners则采用多标靶策略，致力于广泛的肿瘤治疗。北京北地製药代表了中国在该领域的早期开拓者。在多种治疗模式和平行研发路径并存的背景下，多个在研化合物已进入后期临床试验或获得有条件核可阶段，这表明其在再生医学和罕见疾病领域具有巨大的商业潜力。

本报告旨在按地区/国家、类型和应用对全球肝细胞生长因子 (HGF) 市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

肝细胞生长因子市场规模、估算和预测以销售（千）和收入（百万美元）为单位呈现，基准年为2024年，并包含2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定业务/成长策略，评估竞争激烈的市场格局，分析自身在当前市场中的地位，并就肝细胞生长因子做出明智的商业决策。

市场区隔

公司

  • Helixsmith
  • Exelixis
  • AnGes MG
  • Athira Pharma
  • AVEO Pharmaceuticals
  • Molecular Partners
  • Kringle Pharma
  • Beijing Northland

按类型分類的细分市场

  • 第三阶段（进行中）
  • 第二阶段（已通过核准）
  • 第二阶段（进行中）
  • 第一阶段
  • 临床前
  • 已通过核准/已上市

应用领域

  • 肿瘤学
  • 循环系统
  • 中枢神经系统
  • 血液疾病
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Hepatocyte Growth Factor was estimated to be worth US$ 75.8 million in 2024 and is forecast to a readjusted size of US$ 426 million by 2031 with a CAGR of 28.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hepatocyte Growth Factor cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.

Current drug development targeting the HGF pathway is bifurcated into neuroregeneration and oncology tracks, with clinical pipelines focused on indications such as diabetic neuropathy, ALS, spinal cord injury, stroke, and various solid tumors including NSCLC and gastric cancer. Globally, companies like Helixmith, AnGes MG, and Kringle Pharma are advancing gene therapies and recombinant proteins for neurological indications. Athira Pharma and AVEO are developing small molecules and antibodies targeting the HGF/c-Met axis, while Exelixis and Molecular Partners pursue broader oncology strategies via multi-target approaches. Beijing Northland represents China's early-stage involvement in this area. The landscape is marked by diversified modalities and parallel development paths, with several assets reaching late-stage trials or conditional approvals, indicating strong commercialization potential in regenerative medicine and rare diseases.

This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hepatocyte Growth Factor by region & country, by Type, and by Application.

The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.

Market Segmentation

By Company

  • Helixsmith
  • Exelixis
  • AnGes MG
  • Athira Pharma
  • AVEO Pharmaceuticals
  • Molecular Partners
  • Kringle Pharma
  • Beijing Northland

Segment by Type

  • Phase III (Ongoing)
  • Phase II (Approved)
  • Phase II (Ongoing)
  • Phase 1
  • Preclinical
  • Approved / Marketed

Segment by Application

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Hematological Disorders
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Hepatocyte Growth Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Hepatocyte Growth Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Hepatocyte Growth Factor in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Hepatocyte Growth Factor Product Introduction
  • 1.2 Global Hepatocyte Growth Factor Market Size Forecast
    • 1.2.1 Global Hepatocyte Growth Factor Sales Value (2020-2031)
    • 1.2.2 Global Hepatocyte Growth Factor Sales Volume (2020-2031)
    • 1.2.3 Global Hepatocyte Growth Factor Sales Price (2020-2031)
  • 1.3 Hepatocyte Growth Factor Market Trends & Drivers
    • 1.3.1 Hepatocyte Growth Factor Industry Trends
    • 1.3.2 Hepatocyte Growth Factor Market Drivers & Opportunity
    • 1.3.3 Hepatocyte Growth Factor Market Challenges
    • 1.3.4 Hepatocyte Growth Factor Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Hepatocyte Growth Factor Players Revenue Ranking (2024)
  • 2.2 Global Hepatocyte Growth Factor Revenue by Company (2020-2025)
  • 2.3 Global Hepatocyte Growth Factor Players Sales Volume Ranking (2024)
  • 2.4 Global Hepatocyte Growth Factor Sales Volume by Company Players (2020-2025)
  • 2.5 Global Hepatocyte Growth Factor Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Hepatocyte Growth Factor Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Hepatocyte Growth Factor Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Hepatocyte Growth Factor
  • 2.9 Hepatocyte Growth Factor Market Competitive Analysis
    • 2.9.1 Hepatocyte Growth Factor Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Hepatocyte Growth Factor Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocyte Growth Factor as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Phase III (Ongoing)
    • 3.1.2 Phase II (Approved)
    • 3.1.3 Phase II (Ongoing)
    • 3.1.4 Phase 1
    • 3.1.5 Preclinical
    • 3.1.6 Approved / Marketed
  • 3.2 Global Hepatocyte Growth Factor Sales Value by Type
    • 3.2.1 Global Hepatocyte Growth Factor Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Hepatocyte Growth Factor Sales Value, by Type (2020-2031)
    • 3.2.3 Global Hepatocyte Growth Factor Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Hepatocyte Growth Factor Sales Volume by Type
    • 3.3.1 Global Hepatocyte Growth Factor Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Hepatocyte Growth Factor Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Hepatocyte Growth Factor Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Hepatocyte Growth Factor Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Oncology
    • 4.1.2 Cardiovascular
    • 4.1.3 Central Nervous System
    • 4.1.4 Hematological Disorders
    • 4.1.5 Others
  • 4.2 Global Hepatocyte Growth Factor Sales Value by Application
    • 4.2.1 Global Hepatocyte Growth Factor Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Hepatocyte Growth Factor Sales Value, by Application (2020-2031)
    • 4.2.3 Global Hepatocyte Growth Factor Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Hepatocyte Growth Factor Sales Volume by Application
    • 4.3.1 Global Hepatocyte Growth Factor Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Hepatocyte Growth Factor Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Hepatocyte Growth Factor Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Hepatocyte Growth Factor Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Hepatocyte Growth Factor Sales Value by Region
    • 5.1.1 Global Hepatocyte Growth Factor Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Hepatocyte Growth Factor Sales Value by Region (2020-2025)
    • 5.1.3 Global Hepatocyte Growth Factor Sales Value by Region (2026-2031)
    • 5.1.4 Global Hepatocyte Growth Factor Sales Value by Region (%), (2020-2031)
  • 5.2 Global Hepatocyte Growth Factor Sales Volume by Region
    • 5.2.1 Global Hepatocyte Growth Factor Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025)
    • 5.2.3 Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031)
    • 5.2.4 Global Hepatocyte Growth Factor Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Hepatocyte Growth Factor Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.4.2 North America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.5.2 Europe Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Hepatocyte Growth Factor Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.7.2 South America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Hepatocyte Growth Factor Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Hepatocyte Growth Factor Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.3.2 United States Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.4.2 Europe Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.5.2 China Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.6.2 Japan Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.7.2 South Korea Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.9.2 India Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Helixsmith
    • 7.1.1 Helixsmith Company Information
    • 7.1.2 Helixsmith Introduction and Business Overview
    • 7.1.3 Helixsmith Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Helixsmith Hepatocyte Growth Factor Product Offerings
    • 7.1.5 Helixsmith Recent Development
  • 7.2 Exelixis
    • 7.2.1 Exelixis Company Information
    • 7.2.2 Exelixis Introduction and Business Overview
    • 7.2.3 Exelixis Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Exelixis Hepatocyte Growth Factor Product Offerings
    • 7.2.5 Exelixis Recent Development
  • 7.3 AnGes MG
    • 7.3.1 AnGes MG Company Information
    • 7.3.2 AnGes MG Introduction and Business Overview
    • 7.3.3 AnGes MG Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 AnGes MG Hepatocyte Growth Factor Product Offerings
    • 7.3.5 AnGes MG Recent Development
  • 7.4 Athira Pharma
    • 7.4.1 Athira Pharma Company Information
    • 7.4.2 Athira Pharma Introduction and Business Overview
    • 7.4.3 Athira Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Athira Pharma Hepatocyte Growth Factor Product Offerings
    • 7.4.5 Athira Pharma Recent Development
  • 7.5 AVEO Pharmaceuticals
    • 7.5.1 AVEO Pharmaceuticals Company Information
    • 7.5.2 AVEO Pharmaceuticals Introduction and Business Overview
    • 7.5.3 AVEO Pharmaceuticals Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 AVEO Pharmaceuticals Hepatocyte Growth Factor Product Offerings
    • 7.5.5 AVEO Pharmaceuticals Recent Development
  • 7.6 Molecular Partners
    • 7.6.1 Molecular Partners Company Information
    • 7.6.2 Molecular Partners Introduction and Business Overview
    • 7.6.3 Molecular Partners Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Molecular Partners Hepatocyte Growth Factor Product Offerings
    • 7.6.5 Molecular Partners Recent Development
  • 7.7 Kringle Pharma
    • 7.7.1 Kringle Pharma Company Information
    • 7.7.2 Kringle Pharma Introduction and Business Overview
    • 7.7.3 Kringle Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Kringle Pharma Hepatocyte Growth Factor Product Offerings
    • 7.7.5 Kringle Pharma Recent Development
  • 7.8 Beijing Northland
    • 7.8.1 Beijing Northland Company Information
    • 7.8.2 Beijing Northland Introduction and Business Overview
    • 7.8.3 Beijing Northland Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Beijing Northland Hepatocyte Growth Factor Product Offerings
    • 7.8.5 Beijing Northland Recent Development

8 Industry Chain Analysis

  • 8.1 Hepatocyte Growth Factor Industrial Chain
  • 8.2 Hepatocyte Growth Factor Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Hepatocyte Growth Factor Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Hepatocyte Growth Factor Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Hepatocyte Growth Factor Market Trends
  • Table 2. Hepatocyte Growth Factor Market Drivers & Opportunity
  • Table 3. Hepatocyte Growth Factor Market Challenges
  • Table 4. Hepatocyte Growth Factor Market Restraints
  • Table 5. Global Hepatocyte Growth Factor Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Hepatocyte Growth Factor Revenue Market Share by Company (2020-2025)
  • Table 7. Global Hepatocyte Growth Factor Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Hepatocyte Growth Factor Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Hepatocyte Growth Factor Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Hepatocyte Growth Factor Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Hepatocyte Growth Factor Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Hepatocyte Growth Factor
  • Table 13. Global Hepatocyte Growth Factor Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocyte Growth Factor as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Hepatocyte Growth Factor Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Hepatocyte Growth Factor Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Hepatocyte Growth Factor Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Hepatocyte Growth Factor Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Hepatocyte Growth Factor Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Hepatocyte Growth Factor Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Hepatocyte Growth Factor Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Hepatocyte Growth Factor Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Hepatocyte Growth Factor Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Hepatocyte Growth Factor Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Hepatocyte Growth Factor Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Hepatocyte Growth Factor Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Hepatocyte Growth Factor Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Hepatocyte Growth Factor Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Hepatocyte Growth Factor Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Hepatocyte Growth Factor Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Hepatocyte Growth Factor Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Hepatocyte Growth Factor Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Hepatocyte Growth Factor Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Hepatocyte Growth Factor Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Hepatocyte Growth Factor Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Hepatocyte Growth Factor Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Hepatocyte Growth Factor Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Hepatocyte Growth Factor Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Hepatocyte Growth Factor Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Hepatocyte Growth Factor Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Hepatocyte Growth Factor Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Hepatocyte Growth Factor Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Hepatocyte Growth Factor Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Hepatocyte Growth Factor Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Hepatocyte Growth Factor Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Hepatocyte Growth Factor Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Hepatocyte Growth Factor Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Hepatocyte Growth Factor Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Hepatocyte Growth Factor Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Hepatocyte Growth Factor Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Hepatocyte Growth Factor Sales Volume, (2026-2031) & (K Units)
  • Table 57. Helixsmith Company Information
  • Table 58. Helixsmith Introduction and Business Overview
  • Table 59. Helixsmith Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Helixsmith Hepatocyte Growth Factor Product Offerings
  • Table 61. Helixsmith Recent Development
  • Table 62. Exelixis Company Information
  • Table 63. Exelixis Introduction and Business Overview
  • Table 64. Exelixis Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Exelixis Hepatocyte Growth Factor Product Offerings
  • Table 66. Exelixis Recent Development
  • Table 67. AnGes MG Company Information
  • Table 68. AnGes MG Introduction and Business Overview
  • Table 69. AnGes MG Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. AnGes MG Hepatocyte Growth Factor Product Offerings
  • Table 71. AnGes MG Recent Development
  • Table 72. Athira Pharma Company Information
  • Table 73. Athira Pharma Introduction and Business Overview
  • Table 74. Athira Pharma Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Athira Pharma Hepatocyte Growth Factor Product Offerings
  • Table 76. Athira Pharma Recent Development
  • Table 77. AVEO Pharmaceuticals Company Information
  • Table 78. AVEO Pharmaceuticals Introduction and Business Overview
  • Table 79. AVEO Pharmaceuticals Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. AVEO Pharmaceuticals Hepatocyte Growth Factor Product Offerings
  • Table 81. AVEO Pharmaceuticals Recent Development
  • Table 82. Molecular Partners Company Information
  • Table 83. Molecular Partners Introduction and Business Overview
  • Table 84. Molecular Partners Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Molecular Partners Hepatocyte Growth Factor Product Offerings
  • Table 86. Molecular Partners Recent Development
  • Table 87. Kringle Pharma Company Information
  • Table 88. Kringle Pharma Introduction and Business Overview
  • Table 89. Kringle Pharma Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Kringle Pharma Hepatocyte Growth Factor Product Offerings
  • Table 91. Kringle Pharma Recent Development
  • Table 92. Beijing Northland Company Information
  • Table 93. Beijing Northland Introduction and Business Overview
  • Table 94. Beijing Northland Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Beijing Northland Hepatocyte Growth Factor Product Offerings
  • Table 96. Beijing Northland Recent Development
  • Table 97. Key Raw Materials Lists
  • Table 98. Raw Materials Key Suppliers Lists
  • Table 99. Hepatocyte Growth Factor Downstream Customers
  • Table 100. Hepatocyte Growth Factor Distributors List
  • Table 101. Research Programs/Design for This Report
  • Table 102. Key Data Information from Secondary Sources
  • Table 103. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Hepatocyte Growth Factor Product Picture
  • Figure 2. Global Hepatocyte Growth Factor Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Hepatocyte Growth Factor Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Hepatocyte Growth Factor Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Hepatocyte Growth Factor Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Hepatocyte Growth Factor Report Years Considered
  • Figure 7. Global Hepatocyte Growth Factor Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Hepatocyte Growth Factor Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Hepatocyte Growth Factor Revenue in 2024
  • Figure 10. Hepatocyte Growth Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Phase III (Ongoing) Picture
  • Figure 12. Phase II (Approved) Picture
  • Figure 13. Phase II (Ongoing) Picture
  • Figure 14. Phase 1 Picture
  • Figure 15. Preclinical Picture
  • Figure 16. Approved / Marketed Picture
  • Figure 17. Global Hepatocyte Growth Factor Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Hepatocyte Growth Factor Sales Value Market Share by Type, 2024 & 2031
  • Figure 19. Global Hepatocyte Growth Factor Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 20. Global Hepatocyte Growth Factor Sales Volume Market Share by Type, 2024 & 2031
  • Figure 21. Global Hepatocyte Growth Factor Price by Type (2020-2031) & (USD/Unit)
  • Figure 22. Product Picture of Oncology
  • Figure 23. Product Picture of Cardiovascular
  • Figure 24. Product Picture of Central Nervous System
  • Figure 25. Product Picture of Hematological Disorders
  • Figure 26. Product Picture of Others
  • Figure 27. Global Hepatocyte Growth Factor Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 28. Global Hepatocyte Growth Factor Sales Value Market Share by Application, 2024 & 2031
  • Figure 29. Global Hepatocyte Growth Factor Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 30. Global Hepatocyte Growth Factor Sales Volume Market Share by Application, 2024 & 2031
  • Figure 31. Global Hepatocyte Growth Factor Price by Application (2020-2031) & (USD/Unit)
  • Figure 32. North America Hepatocyte Growth Factor Sales Value (2020-2031) & (US$ Million)
  • Figure 33. North America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Europe Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Asia Pacific Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Asia Pacific Hepatocyte Growth Factor Sales Value by Region (%), 2024 VS 2031
  • Figure 38. South America Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. South America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Middle East & Africa Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Middle East & Africa Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 42. Key Countries/Regions Hepatocyte Growth Factor Sales Value (%), (2020-2031)
  • Figure 43. Key Countries/Regions Hepatocyte Growth Factor Sales Volume (%), (2020-2031)
  • Figure 44. United States Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. United States Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 46. United States Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Europe Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Europe Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Europe Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 50. China Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. China Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 52. China Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Japan Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Japan Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Japan Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 56. South Korea Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. South Korea Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 58. South Korea Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Southeast Asia Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 60. Southeast Asia Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 61. Southeast Asia Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 62. India Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 63. India Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 64. India Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 65. Hepatocyte Growth Factor Industrial Chain
  • Figure 66. Hepatocyte Growth Factor Manufacturing Cost Structure
  • Figure 67. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 68. Bottom-up and Top-down Approaches for This Report
  • Figure 69. Data Triangulation
  • Figure 70. Key Executives Interviewed